TY - JOUR
T1 - Global estimates on the number of people blind or visually impaired by age-related macular degeneration
T2 - a meta-analysis from 2000 to 2020
AU - Vision Loss Expert Group of the Global Burden of Disease Study
AU - GBD 2019 Blindness and Vision Impairment Collaborators
AU - Furtado, João M.
AU - Jonas, Jost B.
AU - Tapply, Ian
AU - Fernandes, Arthur G.
AU - Cicinelli, Maria Vittoria
AU - Arrigo, Alessandro
AU - Leveziel, Nicolas
AU - Resnikoff, Serge
AU - Taylor, Hugh R.
AU - Sedighi, Tabassom
AU - Flaxman, Seth
AU - Battaglia Parodi, Maurizio
AU - Bikbov, Mukkharram M.
AU - Braithwaite, Tasanee
AU - Bron, Alain
AU - Cheng, Ching Yu
AU - Congdon, Nathan
AU - Del Monte, Monte A.
AU - Fricke, Tim
AU - Bhaskar, Sonu
AU - Naik, Ganesh R.
AU - Osuagwu, Uchechukwu Levi
AU - et al.,
PY - 2024/8
Y1 - 2024/8
N2 - Background: We aimed to update estimates of global vision loss due to age-related macular degeneration (AMD). Methods: We did a systematic review and meta-analysis of population-based surveys of eye diseases from January, 1980, to October, 2018. We fitted hierarchical models to estimate the prevalence of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (< 3/60) caused by AMD, stratified by age, region, and year. Results: In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77). The crude prevalence of AMD-related blindness in 2020 (among those aged ≥ 50 years) was 0.10% (0.07 to 0.12) globally, and the region with the highest prevalence of AMD-related blindness was North Africa/Middle East (0.22%; 0.16 to 0.30). Age-standardized prevalence (using the GBD 2019 data) of AMD-related MSVI in people aged ≥ 50 years in 2020 was 0.34% (0.27 to 0.41) globally, and the region with the highest prevalence of AMD-related MSVI was also North Africa/Middle East (0.55%; 0.44 to 0.68). From 2000 to 2020, the estimated crude prevalence of AMD-related blindness decreased globally by 19.29%, while the prevalence of MSVI increased by 10.08%. Conclusions: The estimated increase in the number of individuals with AMD-related blindness and MSVI globally urges the creation of novel treatment modalities and the expansion of rehabilitation services.
AB - Background: We aimed to update estimates of global vision loss due to age-related macular degeneration (AMD). Methods: We did a systematic review and meta-analysis of population-based surveys of eye diseases from January, 1980, to October, 2018. We fitted hierarchical models to estimate the prevalence of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (< 3/60) caused by AMD, stratified by age, region, and year. Results: In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77). The crude prevalence of AMD-related blindness in 2020 (among those aged ≥ 50 years) was 0.10% (0.07 to 0.12) globally, and the region with the highest prevalence of AMD-related blindness was North Africa/Middle East (0.22%; 0.16 to 0.30). Age-standardized prevalence (using the GBD 2019 data) of AMD-related MSVI in people aged ≥ 50 years in 2020 was 0.34% (0.27 to 0.41) globally, and the region with the highest prevalence of AMD-related MSVI was also North Africa/Middle East (0.55%; 0.44 to 0.68). From 2000 to 2020, the estimated crude prevalence of AMD-related blindness decreased globally by 19.29%, while the prevalence of MSVI increased by 10.08%. Conclusions: The estimated increase in the number of individuals with AMD-related blindness and MSVI globally urges the creation of novel treatment modalities and the expansion of rehabilitation services.
UR - https://www.scopus.com/pages/publications/85199813397
U2 - 10.1038/s41433-024-03050-z
DO - 10.1038/s41433-024-03050-z
M3 - Article
C2 - 38965321
AN - SCOPUS:85199813397
SN - 0950-222X
VL - 38
SP - 2070
EP - 2082
JO - Eye (Basingstoke)
JF - Eye (Basingstoke)
IS - 11
ER -